Evotec SE

NASDAQ:EVO

Drug Manufacturers - Specialty & Generic

Healthcare
$1.46 -0.57%

-$0.02 today

Market cap
$518.56M
Beta
1.30
P/E (TTM)
-4.2
EPS (TTM)
-$1.09
52W Low $2.31High $4.42

Volume 0.04M

Average 0.08M

EVO Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

Evotec SENASDAQ: EVO

Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Investing cash flow dips below year-ago levels

Q1 FY2026 investing cash flow of €14.54M (cash outflow) fell 32.7% year over year, behind the +356.9% change in trailing-twelve-month investing cash flow.

Context

  • Investing cash flow amounted to 21.1% of revenue in FY2025, up 12.2 pp from a year earlier.
  • Investing cash flow increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -32.7% toward the trailing-twelve-month pace of +356.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-€14.54M-106.8% QoQ
Last fiscal yearDec 2025
€159.86M+324.6% YoY
LTMMar 2026
€169.6M+356.9% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-32.7%——
1 year+324.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

EUR · from the cash flow

Latest · FY2025
159.86M EUR
Year-over-year change
+324.6%

Investing Cash Flow vs competitors

How EVO compares with its peers on the latest reported figures

  • Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +356.9% is the 3rd highest of 11, against a peer median of +99.8%.
  • Investing cash flow amounts to 22.8% of revenue for EVO, versus a peer median of 19.7%.
EVO Competitors
Investing Cash Flow for EVO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SYRESpyre Therapeutics, Inc.LTM Sep 2026$492.54M USD+639.4%—544.3%
NVCRNovoCure LimitedLTM Mar 2026$451.5M USD+214.9%—66.9%
SDGRSchrödinger, Inc.LTM Sep 2026$180.57M USD+1712.0%-13.7%67.1%
TDOCTeladoc Health, Inc.LTM Mar 2026$179.26M USD-15.4%+16.6%7.1%
EVOEvotec SELTM Mar 2026€169.6M EUR+356.9%—22.8%
PCRXPacira BioSciences, Inc.LTM Mar 2026$144.55M USD+254.8%—19.7%
ALVOAlvotechLTM Mar 2026$130.02M USD+263.3%+17.9%23.2%
AZTAAzenta, Inc.LTM Sep 2026$33.8M USD-62.6%—5.4%
HROWHarrow Health, Inc.LTM Mar 2026$23.45M USD-29.5%+46.3%8.7%
TLRYTilray Brands, Inc.LTM Feb 2026$2.18M USD-88.9%+33.2%0.2%
PHVSPharvaris N.V.LTM Sep 2026€81.4K EUR-74.9%+9.8%—
Peer median (excluding EVO) —+99.8%+17.3%19.7%

Competitors are the stored peer set for EVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income215.51M(175.66M)(83.91M)(196.08M)(99.43M)
Depreciation & Amortization67.61M83.2M92.98M101.62M95.55M
Deferred Income Tax5.07M21.7M3.32M2.1M14.11M
Stock-Based Compensation7.81M9.92M9.63M5.04M0
Change in Working Capital(2.28M)105.29M(9.94M)(68.21M)(58.4M)
Accounts Receivables(48.03M)(53.68M)00(27.6M)
Inventory(11.65M)(4.41M)00(9.18M)
Accounts Payables31.34M24.55M00(7.02M)
Other Working Capital26.06M138.83M(9.94M)(68.21M)(14.61M)
Other Non-Cash Items(171.47M)161.37M24.37M173.75M39.11M
Operating Cash Flow122.24M205.81M36.44M18.22M(9.06M)
Capital Expenditures(118.94M)(181.35M)(216M)(132.24M)(69.68M)
Acquisitions (Net)(21.09M)(83.82M)(20.16M)42.78M213.76M
Purchases of Investments(123.7M)(355.82M)(48.39M)(29.39M)(13.42M)
Sales of Investments27.25M205.17M260.36M35.67M38.87M
Other Investing Activities(7.38M)3.03M8.22M(2.78M)0
Investing Cash Flow(243.86M)(412.8M)(13.29M)(71.19M)159.86M
Debt Repayment14.77M(53.11M)84.6M(152.07M)(6.96M)
Common Stock Issued404.32M355K00(1.27M)
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(20.67M)(5.39M)(12.63M)(9.35M)(22.71M)
Financing Cash Flow398.43M(58.15M)71.96M(161.42M)(30.93M)
Effect of Forex Changes(66K)(19.04M)644K9.87M28.46M
Net Change in Cash276.75M(284.17M)95.75M(204.52M)148.32M
Free Cash Flow3.29M24.46M(179.56M)(114.02M)(78.74M)

Evotec SE

NASDAQ:EVO

Intrinsic Alpha fair value

Locked

Current Price

$1.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.